ESMO 2023 | Response-adaptive treatment de-escalation in patients with HPV+ oropharyngeal cancer

Ari Rosenberg, MD, The University of Chicago Medical Center, Chicago, IL, discusses how clinicians can monitor patients with HPV+ oropharyngeal cancer after the administration of neoadjuvant chemotherapy to measure depth of response, allowing a contextual decision to be made on whether treatment de-escalation is applicable. Dr Rosenburg elaborates on how de-escalation can ameliorate a patient’s quality of life, and reduce the burden of short and long-term treatment toxicities. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.